OPF-310: How a Pig-Derived Cell Therapy Could Change Type 1 Diabetes Treatment

OPF-310 is a cell therapy currently in clinical trials for type 1 diabetes. It works by replacing the insulin-producing beta cells that the immune system destroys in type 1 diabetes. These replacement cells come from pig islets—clusters of insulin-producing cells from the pancreas.

Cell therapies represent one of the most promising research directions toward cures for type 1 diabetes. Nearly a dozen cell therapies are currently in clinical testing, and OPF-310 is one of the furthest along using porcine-derived cells.

Most cell therapies in development use insulin-producing cells harvested from human deceased donor pancreases or manufactured in a laboratory. OPF-310 takes a different approach by using cells from pigs—an approach called xenotransplantation.

Xenotransplantation involves transplanting organs, tissues, or cells from animals into humans. This strategy addresses a critical bottleneck: there simply aren't enough human donor pancreases available for everyone who could benefit from cell therapy. Xenotransplantation is being explored in clinical trials not only for islet transplantation, but also for kidney transplantation.

Using porcine-derived cells is not entirely new territory. Before widely available synthetic insulin, insulin derived from pigs was a standard treatment for diabetes for decades.

Any transplanted cells from an outside source—whether from a human donor or an animal—can trigger an immune response as the body recognizes them as foreign and tries to destroy them. This is a major hurdle for cell therapies.

OPF-310's key innovation is an encapsulation device that wraps the pig-derived islets, shielding them from destructive immune cells. This protection means recipients may not need immunosuppressive drugs—medications that suppress the immune system to prevent rejection.

This is a significant advantage. The only FDA-approved cell therapy for type 1 diabetes (Lantidra®) and most cell therapies currently in clinical testing require immunosuppression. For many people, the need for lifelong immune-suppressing drugs can be a barrier to choosing cell therapy. If OPF-310 succeeds, it could change that calculation.

OPF-310 remains in clinical trials, and more research is needed to confirm its safety and effectiveness. The encapsulation approach is still being tested to ensure it provides reliable, long-term protection while allowing insulin to reach the bloodstream where it's needed.

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.